Valuation check: DMAQU's ROE is -558.39%, below the sector sector average of -5.87%.
Get informed when a big investor buys or sells
+ Follow-558.39%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right) posts a ROE of -558.39%. That is below the sector sector average of -5.87%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a ROE near -5.87% is typical. Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s -558.39% is lower that level. That is roughly 9415.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -558.39%; use YoY and peer views to separate noise from signal.
Context for DMAQU's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -5.87%), and (3) consistency with growth and profitability. This page covers the first two; Deep Medicine Acquisition - Units (1 Ord Share Class A , 1Right)'s other metric pages and overview cover the third.